logo-loader
viewProactive Group

Shares of Menlo Therapeutics set to plunge on failure of skin-condition treatment in trial study

The shares of the company dropped 60% in pre-market trading

A vial of pills
The treatment targeted atopic dermatitis

Shares of Menlo Therapeutics Inc. (NASDAQ:MNLO) are poised to plunge in trading today after the company said a trial study of its skin-condition treatment failed to produce “significant” results.

The stock of the biopharmaceutical firm declined 60% to US$21.22 in pre-market trading.

Failed to meet primary endpoint

“The study did not meet its primary or key secondary efficacy endpoints with no statistically significant difference demonstrated between the serlopitant treated groups and the placebo treated group,” Menlo said in a statement.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Proactive One2One Virtual Event - FansUnite Entertainment

FansUnite Entertainment Inc (CSE:FANS) (OTCMKTS:FUNFF) CEO Scott Burton and President Darius Eghdami present to investors at Proactive's One2One Virtual Event. The company focuses on technology related to regulated and lawful online sports betting and other related products.

16 minutes ago

2 min read